Do You Believe in the Upside Potential of Madrigal Pharmaceuticals (MDGL)?
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Madrigal Pharmaceuticals Inc. (MDGL)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 2,141,701 | $982,312,581 | +9% | 7.1% |
| 2. | Paulson & Co John Paulson | 1,907,523 | $874,904,499 | -9% | 29.46% |
| 3. | VenBio Select Advisor Kurt Von Emster | 1,833,000 | $840,723,780 | -3% | 10.87% |
| 4. | Polar Capital Brian Ashford-Russell And Tim Woolley | 265,154 | $121,615,534 | +18% | 0.59% |
| 5. | Hood River Capital Management David Swank | 242,808 | $111,366,317 | -1% | 1.31% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $392.24 | 9,362 | $3,672,178.03 | 1,947,968 | 2025-08-20 | Filing | |
| $392.24 | 862 | $338,113.38 | 202,813 | 2025-08-20 | Filing | |
| $389.89 | 2,506 | $977,058.83 | 1,938,606 | 2025-08-20 | Filing | |
| $389.89 | 231 | $90,064.08 | 201,951 | 2025-08-20 | Filing | |
| $389.00 | 366 | $142,374.00 | 1,936,100 | 2025-08-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $564.57 | 80 | $45,165.20 | 10,032 | 2025-11-21 | Filing | |
| $563.21 | 40 | $22,528.40 | 10,112 | 2025-11-21 | Filing | |
| $560.62 | 80 | $44,849.60 | 10,152 | 2025-11-21 | Filing | |
| $559.60 | 200 | $111,919.60 | 10,232 | 2025-11-21 | Filing | |
| $556.04 | 120 | $66,724.80 | 10,432 | 2025-11-21 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,993,687 | $914,424,479 | 11.27% | |
| 2. | 1,842,690 | $845,277,273 | 0.39% | |
| 3. | 1,812,054 | $831,116,688 | 0.01% | |
| 4. | 1,559,712 | $715,377,705 | 0.01% | |
| 5. | 658,097 | $301,842,770 | 0.01% |
News See All
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q3 2025 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q3 2025 Earnings Call Transcript November 4, 2025Madrigal Pharmaceuticals, Inc. misses on earnings expectations.
TD Cowen Sees Greater Upside in Madrigal (MDGL) Following Recent Rezdiffra Approval
Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the most shorted stocks right now.
10 Most Shorted Stocks Right Now
Short interest has become one of the most closely followed indicators in today’s market.
13 Best Mid Cap Growth Stocks to Buy According to Hedge Funds
On August 26, Courtney Garcia, Payne Capital Management senior wealth advisor, joined CNBC television for an interview to discuss whether investors should continue buying in the current market scenario...
Do You Believe in the Upside Potential of Madrigal Pharmaceuticals (MDGL)?
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q2 2025 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q2 2025 Earnings Call Transcript August 5, 2025Madrigal Pharmaceuticals, Inc. beats earnings expectations.
Madrigal Pharmaceuticals, Inc. (MDGL)’s Rezdiffra Hits 51% Liver Stiffness Reduction in Phase 3
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is leading innovation in treating metabolic dysfunction-associated steatohepatitis (MASH), previously known as NASH.
Madrigal (MDGL) Secures $500M to Fuel MASH Pipeline Expansion
Madrigal Pharmaceuticals (NASDAQ:MDGL) is one of the best biotech stocks to buy according to billionaire Steve Cohen.
10 Best Biotech Stocks to Buy According to Billionaire Steve Cohen
Steve Cohen, whose success at SAC Capital made him one of the most successful hedge fund managers on Wall Street, is a worried man.